肝源性糖尿病患者肝组织干扰素诱导蛋白-10表达变化*

doi:10.3969/j.issn.1672-5069.2019.05.019

Abstract

Abstract: Objective To investigate hepatic expression of interferon inducible protein -10 （IP-10） in patients with hepatitis B liver cirrhosis and hepatogenic diabetes mellitus. Methods The specimens of liver tissues from 70 patients with hepatitis B-induced liver cirrhosis and hepatogenic diabetes mellitus and another 70 patients with hepatitis B-induced liver cirrhosis were obtained by liver biopsies between March 2016 and May 2018,and serum IP-10 were assayed by ELISA,and hepatic IP-10 mRNA and its protein expression were detected by PCR and immunohistochemistry. Results Serum IP-10 level in patients with hepatitis B-induced liver cirrhosis and hepatogenic diabetes mellitus was （236.59±28.30） pg/mL,significantly higher than [（205.31±26.92） pg/mL,P<0.001] in patient with liver cirrhosis without hepatogenic diabetes mellitus; hepatic IP-10 mRNA was （0.59±0.91）,significantly higher than [（0.21±0.66）,P<0.05] in patients without diabetes mellitus;the immunohistochemical staining results showed that the hepatic IP-10 expression positive rate was 31.4%,significantly higher than（12.9%,x2=7.002,P<0.05） in patients without diabetes mellitus. Conclusion The expression of IP-10 in liver tissues and serum IP-10 levels in patients with hepatogenic diabetes mellitus with underlying hepatitis B liver cirrhosis is sig-nificantly increased,which might be involved in the pathogenesis of hepatogenic diabetes mellitus through inflammatory mechanism.

Key words: Liver cirrhosis, Hepatitis B, Hepatogenic diabetes mellitus, Interferon inducible protein-10, Liver histopathology

Zhang Mei, Shi Xiuying, Li Linjuan, et al. Hepatic expression of interferon inducible protein -10 in patients with hepatitis B liver cirrhosis and hepatogenic diabetes mellitus[J]. Journal of Practical Hepatology, 2019, 22(5): 688-691.

References

[1] Shoko K,Yoshiyuki M,Hideki F,et al.Prevalence of diabetes and incidence of angiopathy in patients with chronic viral liver disease. J Clin Biochem Nutrit,2007,40(2):116-122.
[2] Marchesini G,Ronchi M,Forlani G,et al.Cardiovascular disease in cirrhosis-a point-prevalence study in relation to glucose tolerance. Am J Gastroenterol,1999,94(3):655-662.
[3] Sauty A,Dziejman M,Taha RA,et al.The T cell-specific CXC chemokines IP-10,Mig,and I-TAC are expressed by activated human bronchial epithelial cells. J Immunol,1999,162(6):3549-3558.
[4] 李子月,赵彩彦. 干扰素诱导蛋白10在慢性乙型肝炎病毒感染中的作用及其对抗病毒疗效的评价. 中华传染病杂志,2015,34(8):502-504.
[5] 中华医学会肝病学分会和感染病学分会.慢性乙型肝炎防治指南(2015年版).实用肝脏病杂志,2016,19(3):Ⅴ-ⅩⅩⅢ.
[6] Matthias K,Sascha B,Hermann-Georg H.Quantifying the contribution of the liver to glucose homeostasis:a detailed kinetic model of human hepatic glucose metabolism. PLoS Comput Biol, 2012,8(6):e1002577.
[7] Fukuda K,Taniguchi H,Koh T,et al.Relationships between oxygen and glucose metabolism in human liver tumours:positron emission tomography using(15)O and (18)F-deoxyglucose. Nucl Med Commun,2004,25(6):577-583.
[8] 涂盛,邵安文,叶真,等. 肝源性糖尿病发病机制研究进展. 中华肝脏病杂志,2014,22(1):78-80.
[9] 傅蓓蓓,吴金明,徐美,等. 肝硬化患者发生肝源性糖尿病的多因素Logistic回归分析. 中华肝脏病杂志,2015,23(6):464-466.
[10] Narita R,Abe S,Tabaru A,et al.Impact of steatosis on insulin secretion in chronic hepatitis C patients. Am J Gastroenterol,2007,102(10):2173.
[11] Sampelean D,Hanescu B,Han A,et al.The prognosis of glycoregulation disturbances and insulin secretion in alcoholic and C virus liver cirrhosis. Rom J Intern Med,2009,47(4):387.
[12] Penny C D,Scott P R,Mueller K,et al.Diabetes mellitus associated with lymphocytic islet inflammation in a charolais bull.Vet Rec,2001,148(9):275-276.
[13] Hall DG,Kelley LC,Gray ML,et al.Lymphocytic inflammation of pancreatic islets in a diabetic cat. J Vet Diagn Invest,1997,9(1):98.
[14] Min F,Wu R,Pan J,et al.Positive correlation between IP-10 and IFN-γ levels in rhesus monkeys (macaca mulatta) with either naturally acquired or experimental infection of mycobacterium tuberculosis. Biomed Res Int,2017,2017(9):1-6.
[15] Mihm S,Schweyer S,Ramadori G.Expression of the chemokine IP-10 correlates with the accumulation of hepatic IFN-gamma and IL-18 mRNA in chronic hepatitis C but not in hepatitis B. J Med Virol,2003,70(4):562.
[16] Katz JD,Benoist C,Mathis D.T helper cell subsets in insulin-dependent diabetes. Science,1995,268(5214):1185-1188.
[17] 陆恩词,朱颖蔚,端木和运,等. 糖尿病患者肺结核感染外周血Th1/Th2细胞因子的测定与临床意义. 中华医院感染学杂志,2015,25(20):4624-4626.
[18] Liu D,Cardozo AK,Darville MI,et al.Double-stranded RNA cooperates with interferon-gamma and IL-1 beta to induce both chemokine expression and nuclear factor-kappa B-dependent apoptosis in pancreatic beta-cells: potential mechanisms for viral-induced insulitis and beta-cell death in type 1 d. Endocrinology,2002,143(4):1225-1234.
[19] Cardozo AK,Proost P,Gysemans C,et al.IL-1β and IFN-γ induce the expression of diverse chemokines and IL-15 in human and rat pancreatic islet cells,and in islets from pre-diabetic NOD mice. Diabetologia,2003,46(2):255-266.
[20] 乔月芹,李俊英,匡湧,等. 慢性乙型肝炎患者肝纤维化的代谢影响因素分析. 中华医院感染学杂志,2016,26(17):3889-3891.
[21] Papatheodoridis GV,Manolakopoulos S,Margariti A,et al.The usefulness of transient elastography in the assessment of patients with HBeAg-negative chronic hepatitis B virus infection. J Viral Hepat,2014,21(7):517.
[22] 刘梅,臧凤,姚轶男,等. 慢性丙型肝炎患者糖代谢异常及其相关因素研究. 中华疾病控制杂志,2017,21(9):909-912.
[23] Pazhanivel M,Jayanthi V.Diabetes mellitus and cirrhosis liver.Minerva Gastroenterol Dietol,2010,56(1):7-11.
[24] Moucari R,Asselah T,Cazals-Hatem D,et al.Insulin resistance in chronic hepatitis C:association with genotypes 1 and 4,serum HCV RNA level,and liver fibrosis. Gastroenterology,2008,134(2):416-423.
[25] Ratge D,Scheiblhuber B,Landt O,et al.Two-round rapid-cycle RT-PCR in single closed capillaries increases the sensitivity of HCV RNA detection and avoids amplicon carry-over. J Clin Virol,2002,24(3):161-172.
[26] 陈仁,廖金瑶,陈文莉,等. 干扰素诱导蛋白10在慢性乙型肝炎病毒感染中的临床作用分析. 中华医院感染学杂志,2016,26(15):3368-3369.
[27] Winhofer Y, Krssák M,Wolf P,et al.Hepatic rather than cardiac steatosis relates to glucose intolerance in women with prior gestational diabetes. Plos One,2014,9(3):e91607.

Hepatic expression of interferon inducible protein -10 in patients with hepatitis B liver cirrhosis and hepatogenic diabetes mellitus

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Zhuang Ying, Lin Zhihui.. Clinical manifestations and diagnosis of portal vein thrombosis [J]. Journal of Practical Hepatology, 2019, 22(6): 765-767.
[2]	chronic hepatitis B Zhu Lingyun, Zhang Maohai Cui Shasha, et al.. Serum IL-12 and IL-18 levels as well as peripheral blood mononuclear cell FOXp3 in patients with [J]. Journal of Practical Hepatology, 2019, 22(6): 816-819.
[3]	Shi Yingying, Wang Yuanxi.. Impact of combination telbivudine and adefovir dipivoxil on renal functions in the treatment of patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(6): 820-823.
[4]	Min Feng, Huang Wenqi, Wu Weibing, et al.. Implications of serum adipocytokine levels in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(6): 824-827.
[5]	patients with chronic hepatitis B Zhang Yingming, Shen Shuang, Tian Fei, et al.. Prediction of response to peginterferon alfa-2a by blood IFNL4 and IL-28B gene polymorphisms in [J]. Journal of Practical Hepatology, 2019, 22(6): 828-831.
[6]	chronic hepatitis B virus carriers Wu Haiyi, Chen Jianxin.. Diagnostic efficacy of four non-invasive diagnostic models in evaluating significant liver fibrosis in [J]. Journal of Practical Hepatology, 2019, 22(6): 832-835.
[7]	Ma Liying, Shen Lijuan.. Efficacy and safety of tenofovir in the treatment of pregnant women with high HBV DNA loads [J]. Journal of Practical Hepatology, 2019, 22(6): 836-839.
[8]	Yang Caiyong, Chen Na, Li Kui, et al.. Clinical significance of peripheral blood Treg and Th17 cells in patients with chronic hepatitis C and hepatitis C-induced liver cirrhosis [J]. Journal of Practical Hepatology, 2019, 22(6): 868-871.
[9]	Wu Dan Ma Xiangying.. Insulin resistance,carotid atherosclerosis and left ventricular function in patients with NAFLD-induced liver cirrhosis [J]. Journal of Practical Hepatology, 2019, 22(6): 876-879.
[10]	He Zhi’an, Yu Liping, Lai Jiangqiong, et al.. Evaluation of varices bleeding and portal vein thrombosis by ARFI in patients with cirrhosis and esophagogastric varices [J]. Journal of Practical Hepatology, 2019, 22(6): 888-891.
[11]	Li Chuanjie, Xu Jing, Wang Liangliang, et al.. Changes of serum HBsAg levels in patients with chronic hepatitis B receiving entecavir treatment [J]. Journal of Practical Hepatology, 2019, 22(6): 928-929.
[12]	Du Keye, Yang Dongliang, Liu Jia. Regulatory T cells in hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 613-616.
[13]	Liao Guichan, Peng Jie, Zhang Xiaoyong. Roles of hepatocytes in intrinsic innate immunity in control of hepatits B virus infection [J]. Journal of Practical Hepatology, 2019, 22(5): 617-619.
[14]	Zhao Xieshan, Wu Chunrong, Wang Chunfeng, et al. Preliminary study on the efficacy of combination of tenofovir and Anluo Huaxian pill in the treatment of patients with HBeAg-negative chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 644-647.
[15]	Tu Jiexia, Wang An’na, Liao Ruoxi. Comparative study of interferon alpha -2b and peginterferon alpha -2a in the treatment of patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 648-651.